Source: Fierce Biotech Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. The acquisition, announced Tuesday, would give Incyte ownership over two budding immunology and inflammation candidates, led by EP262, in development for a handful of inflammatory skin conditions. The second asset,…...
LEO Pharma to Acquire Timber Pharmaceuticals
Source: Dermatology Times LEO Pharma announced today its acquisition of Timber Pharmaceuticals, a transaction valued at $36 million.1 Timber Pharmaceuticals has been evaluating the safety and efficacy of its breakthrough therapy, TMB-001, for the treatment of congenital ichthyosis (CI). TMB-001, a topical isotretinoin formulation, was granted Fast Track Designation in April 2022 and Breakthrough Therapy…...
Rick Beck – Founding Recruiter on Forbes.jobs
Meet Rick Beck, a highly respected executive recruiter with a passion for connecting top talent with leading companies in the pharmaceutical, medical device, and biotechnology industries. With a nationwide reach, Rick and his team use a unique 48-point assessment process to ensure the perfect match between candidate and company. From contract sales…...
L’Oreal to acquire skinbetter science
Clichy, September 23, 2022 – L’Oréal signed an agreement to acquire Skinbetter Science, a physician-dispensed American skincare brand backed by cutting-edge, dermatological science, combining patented efficacious ingredients with luxurious sensorial textures. Skinbetter Science was co-founded in 2016 by pharmaceutical industry professionals, Jonah Shacknai, Justin Smith and Seth Rodner, and has since become one…...
EPI Health Announces Acquisition by Novan, Inc. to Create Fully Integrated Specialty Dermatology Company
Source: EPI Health The EP Group (privately held parent company of EPI Health, Inc.) today announced the acquisition of EPI Health, LLC (“EPI Health”) by Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN). Novan will host a conference call and webcast, today, March 11, 2022, at 8:30 a.m. ET (details…...
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.
Source: GlobeNewswire Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that the company entered into a definitive agreement with VYNE Therapeutics, Inc. (“VYNE”) to acquire its Molecule Stabilizing Technology…...
Journey Medical Corporation Announces Launch of its Initial Public Offering
Source: GlobesNewswire Journey Medical Corporation (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has launched an initial public offering of 3,200,000 shares…...
Amgen reveals midphase eczema data behind its $400M bet
Source: FierceBiotech When Amgen splashed $400 million upfront on Kyowa Kirin’s anti-OX40 antibody, the world was yet to see midphase data on the prospect. Amgen and Kyowa lifted the lid on the data over the weekend in a presentation of phase 2 results in eczema patients. The clinical trial randomized 274 adults…...
Crown Laboratories to Acquire StriVectin®, the #1 Independent Prestige Skincare Company in the U.S.
Source: PR Newswire Crown Laboratories, ("Crown"), a leading, fully integrated, global skincare company and a Hildred Capital Management LLC ("Hildred") portfolio company, and L Catterton, the largest global consumer-focused private equity firm, today announced that they have entered into a definitive agreement under which Crown will acquire StriVectin. The transaction is expected…...
Cassiopea SpA and Sun Pharma Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada
Source: Cassiopea Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing essential dermatological conditions, and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries…...